Adherence to, and effectiveness of, subcutaneous interferon beta-1a administered by RebiSmart (R) in patients with relapsing multiple sclerosis: results of the 1-year, observational SMART study

Antonios Bayas*, Jean Christophe Ouallet, Boris Kallmann, Raymond Hupperts, Ulrich Fulda, Kurt Marhardt

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

30 Citations (Web of Science)


Background: Patients with multiple sclerosis who have poor adherence to treatment have a higher risk of relapse than adherent patients. This study assessed adherence to, and effectiveness and convenience of, treatment with subcutaneous (sc) interferon (IFN) beta-1a (Rebif, Merck Serono SA) 44 or 22 mu g three times weekly in patients with relapsing multiple sclerosis (RMS) using the RebiSmart (R) electronic, multidose, autoinjector for 1 year. Study design: European, multicentre, observational study among neurologists: inclusion criteria included RMS, Expanded Disability Status Scale score
Original languageEnglish
Pages (from-to)1239-1250
JournalExpert Opinion on Drug Delivery
Issue number8
Publication statusPublished - Aug 2015


  • adherence
  • autoinjector
  • interferon beta
  • multiple sclerosis

Cite this